Technical Analysis for ACXP - Acurx Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.40% | |
Calm After Storm | Range Contraction | 0.40% | |
Wide Bands | Range Expansion | 0.40% | |
Gapped Down | Weakness | 0.40% |
Alert | Time |
---|---|
10 DMA Support | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Outside Day | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
Up 2% | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.82 |
52 Week Low | 1.17 |
Average Volume | 75,624 |
200-Day Moving Average | 2.93 |
50-Day Moving Average | 2.13 |
20-Day Moving Average | 2.29 |
10-Day Moving Average | 2.50 |
Average True Range | 0.17 |
RSI (14) | 59.02 |
ADX | 27.93 |
+DI | 24.80 |
-DI | 12.96 |
Chandelier Exit (Long, 3 ATRs) | 2.28 |
Chandelier Exit (Short, 3 ATRs) | 2.37 |
Upper Bollinger Bands | 2.78 |
Lower Bollinger Band | 1.80 |
Percent B (%b) | 0.73 |
BandWidth | 42.55 |
MACD Line | 0.12 |
MACD Signal Line | 0.09 |
MACD Histogram | 0.0256 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.65 | ||||
Resistance 3 (R3) | 2.65 | 2.62 | 2.62 | ||
Resistance 2 (R2) | 2.62 | 2.58 | 2.61 | 2.61 | |
Resistance 1 (R1) | 2.56 | 2.56 | 2.59 | 2.56 | 2.61 |
Pivot Point | 2.53 | 2.53 | 2.54 | 2.52 | 2.53 |
Support 1 (S1) | 2.47 | 2.49 | 2.50 | 2.47 | 2.41 |
Support 2 (S2) | 2.44 | 2.47 | 2.43 | 2.41 | |
Support 3 (S3) | 2.38 | 2.44 | 2.40 | ||
Support 4 (S4) | 2.38 |